IDEXX Laboratories, Inc. $IDXX Shares Sold by Fundsmith LLP

Key Points

• Fundsmith LLP cut its IDEXX Laboratories stake by 30.4% in the second quarter, selling 445,899 shares and retaining 1,019,887 shares worth about $536.9 million. Institutional investors collectively own 87.84% of the company.
• IDEXX exceeded quarterly expectations, reporting $4.27 in EPS and $1.22 billion in revenue, with revenue up 9.7% year over year. The company provided fiscal 2026 EPS guidance of $14.69–$14.94.
• Shares opened at $554.99, near the lower end of their 52-week range, while analysts maintained a “Moderate Buy” consensus and an average price target of $747.

Fundsmith LLP lowered its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 30.4% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,019,887 shares of the company's stock after selling 445,899 shares during the quarter. IDEXX Laboratories comprises about 3.9% of Fundsmith LLP's holdings, making the stock its 15th largest position. Fundsmith LLP owned 1.29% of IDEXX Laboratories worth $536,909,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently bought and sold shares of IDXX. Aurora Investment Managers LLC. purchased a new position in shares of IDEXX Laboratories in the second quarter valued at $2,442,000. Elyxium Wealth LLC bought a new position in shares of IDEXX Laboratories during the fourth quarter valued at approximately $3,666,459,000. NewEdge Wealth LLC increased its position in IDEXX Laboratories by 122.3% in the fourth quarter. NewEdge Wealth LLC now owns 6,597 shares of the company's stock worth $4,463,000 after buying an additional 3,629 shares during the period. Prospera Financial Services Inc bought a new position in IDEXX Laboratories in the 4th quarter worth about $4,188,000. Finally, Fortem Financial Group LLC acquired a new stake in IDEXX Laboratories in the fourth quarter worth about $2,068,000. Hedge funds and other institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Stock Performance

IDXX stock opened at $554.99 on Monday. The company has a current ratio of 1.17, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. The business's 50-day moving average price is $559.01 and its two-hundred day moving average price is $573.33. IDEXX Laboratories, Inc. has a 1-year low of $518.55 and a 1-year high of $769.98. The firm has a market cap of $43.72 billion, a PE ratio of 39.03, a P/E/G ratio of 2.96 and a beta of 1.54.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.94 by $0.33. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The business had revenue of $1.22 billion during the quarter, compared to analysts' expectations of $1.20 billion. During the same period in the prior year, the business earned $3.50 EPS. IDEXX Laboratories's revenue for the quarter was up 9.7% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, research analysts forecast that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have weighed in on IDXX shares. Citigroup lifted their price objective on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 5th. Barclays reduced their price target on shares of IDEXX Laboratories from $800.00 to $710.00 and set an "overweight" rating for the company in a report on Tuesday, August 11th. Weiss Ratings cut shares of IDEXX Laboratories from a "hold (c+)" rating to a "hold (c)" rating in a research note on Thursday. UBS Group boosted their target price on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the company a "neutral" rating in a research note on Wednesday, August 5th. Finally, Wall Street Zen lowered shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Sunday, July 12th. Six equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, IDEXX Laboratories presently has an average rating of "Moderate Buy" and an average target price of $747.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source